Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s):  MYCOF

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.


CSE:MYCO - Post by User

Post by Betteryear2on Nov 03, 2021 7:46am
360 Views
Post# 34080951

Files Full Patent Application

Files Full Patent Application

DENVER, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced the filing of a technology patent that allows for the creation of formulations that utilize nanoemulsion technology to enhance, stabilize and make repeatable properties of ingredients from traditional medicine. The patent will cover formulations that are generally recognized as safe by FDA (GRAS-certified) and leverages increased bioavailability to enhance the properties available to consumers.

Nanoemulsion is an advanced mode of drug delivery that has been developed to overcome the major drawbacks associated with conventional drug delivery systems. This technology is critical to the Company’s active drug development as it provides increased control in delivery, which is an essential feature in microdosing and customizing dosages.

“These GRAS-pending nanotechnology formulations offer a significant opportunity to enhance the bioavailability of natural compounds found in traditional medicine, such as reishi and cordyceps, so that they can be added to an expanding variety of consumer products to achieve enhanced benefits,” said Rob Roscow, Chief Science Officer. “By fine-tuning our ingredients and extraction processes, we are able to deliver these valuable properties more accurately and effectively to consumers.”

“This patent filing marks a key milestone for Mydecine’s drug development pipeline in that we have introduced an additional wall of IP protection that covers important technologically innovative properties of compounds that can empower a number of over the counter supplements and consumer products. The compatibility of these formulas as patent-protected ingredients has Mydecine excited to develop a wide variety of licensing opportunities,” said Josh Bartch, CEO of Mydecine. “We will be able to more easily reach consumers through the expansive retail and wellness markets. As we continue to produce new methods to traditional medicinal roots, it is critical that we apply layerable patented technology to our discovery process in order to enhance the use of extracts and take advantage of increasing demand for these valuable compounds into today’s health treatments.”

Mydecine will continue to develop compounds inspired by traditional ingredients empowered by modern technology to increase the bioavailability of extracts and optimize delivery to consumers. The Company aims to use similar technology in over-the-counter consumer products to increase accessibility and usability.

https://www.globenewswire.com/news-release/2021/11/03/2326263/0/en/Mydecine-Files-Full-Patent-Application-Covering-New-Formulations-that-Bring-Nanoemulsion-Technology-to-Traditional-Medicine-Ingredients.html

<< Previous
Bullboard Posts
Next >>